Analysis
PublicEXELAN PHARMACEUTICALS INC. holds $189.0M across 124 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36F79720D0227. Competition previously drew 3 offers. Recompete timing centers on the Jun 29, 2027 PoP end — agencies typically plan 12–18 months ahead.
Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 76282-0704-45); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 76282-0702-45); 10 CT. BLISTERS PACKS.
Recompete timing
PublicCurrent PoP ends Jun 29, 2027 (317 days remaining). Agencies typically plan 12–18 months ahead — at 10.4 months out, that window is already open. The buying decision is likely already in motion.
Watch this contract — one email →Incumbent footprint
Public recordEXELAN PHARMACEUTICALS INC. — $189.0M obligated across 124 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Track this contract
Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open EXELAN PHARMACEUTICALS INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Frequently asked questions
What is contract 75A50325F80014?
75A50325F80014 (OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 76282-0704-45); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES…) is a Department of Health and Human Services (HHS) award with an estimated value of $74.1M, currently held by EXELAN PHARMACEUTICALS INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.
Who is the incumbent on 75A50325F80014?
EXELAN PHARMACEUTICALS INC. is the incumbent with $189.0M across 124 related awards in SCOUT’s public footprint. The current period of performance ends Jun 29, 2027.
When does 75A50325F80014 come up for recompete?
SCOUT tracks a period-of-performance end of Jun 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →